Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated No phase listed Observational

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

ClinicalTrials.gov ID: NCT02355574

Public ClinicalTrials.gov record NCT02355574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The INTEGRATE Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed. Data will be collected through review of medical records from clinical visits with physician. The purpose is to document the clinical application of results obtained from the DecisionDx- Melanoma multi-gene assay and to track outcomes of patients for whom DecisionDx-Melanoma testing has been completed. Additionally the study will assess the health economic impact of DecisionDx-Melanoma testing as it relates to the Melanoma population.

Study identification

NCT ID
NCT02355574
Recruitment status
Terminated
Study type
Observational
Phase
Not listed
Lead sponsor
Castle Biosciences Incorporated
Industry
Enrollment
301 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2014 (Actual)
Primary completion
Feb 2021 (Actual)
Completion
Jul 2021 (Actual)
Last update posted
Oct 8, 2021

2014 – 2021

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Northside Hospital Atlanta Georgia 30342 —
University of Louisville Louisville Kentucky 40202 —
Saint Louis University St Louis Missouri 63103 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02355574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 8, 2021 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02355574 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →